Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis

Shinji Matsunaga, Taro Kishi, Nakao Iwata

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: There is uncertainty about the efficacy and tolerability of zonisamide for Parkinson's disease (PD). Objective: We performed a meta-analysis of zonisamide treatment in PD patients who received antiparkinson drugs such as levodopa. Methods: The primary outcome measures were the Unified Parkinson's Disease Rating Scale (UPDRS) Part III scores, wearing-off time, and discontinuation rate due to all causes. Secondary outcome measures were UPDRS total and subscale scores; discontinuation rates due to adverse events, inefficacy, and death; and individual adverse events. Results: Four randomized placebo-controlled trials including 1,068 PD patients were analyzed. All studies were conducted in Japan. UPDRS Part III scores were significantly lower with zonisamide than with placebo (weighted mean difference [WMD], -2.56; 95 confidence interval [CI]; -4.20 to -0.92; p=0.002). Further, zonisamide significantly decreased the wearing-off time compared with placebo (standardized mean difference, -0.24; 95 CI, -0.39 to -0.09; p=0.001). Discontinuation rates due to all causes were similar between the zonisamide and placebo groups (risk ratio, 1.29; 95 CI, 0.90 to 1.84; p=0.16). While zonisamide also decreased both UPDRS Part II (off-time) and UPDRS total scores compared to placebo (UPDRS Part II [off-time] scores: WMD, -0.79; UPDRS total scores: WMD, -2.51), there were no significant differences in other secondary outcomes between the two groups. Conclusions: Our results suggested that zonisamide combination therapy was beneficial in treating motor symptoms in PD patients receiving antiparkinson drugs and was well tolerated in Japanese patients. Future studies in populations other than the Japanese are needed.

Original languageEnglish
Pages (from-to)1229-1239
Number of pages11
JournalJournal of Alzheimer's Disease
Volume56
Issue number4
DOIs
Publication statusPublished - 01-01-2017

Fingerprint

zonisamide
Antiparkinson Agents
Parkinson Disease
Meta-Analysis
Placebos
Therapeutics
Confidence Intervals
Outcome Assessment (Health Care)

All Science Journal Classification (ASJC) codes

  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

@article{3b07106097744ffd98ff052138dd6c32,
title = "Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis",
abstract = "Background: There is uncertainty about the efficacy and tolerability of zonisamide for Parkinson's disease (PD). Objective: We performed a meta-analysis of zonisamide treatment in PD patients who received antiparkinson drugs such as levodopa. Methods: The primary outcome measures were the Unified Parkinson's Disease Rating Scale (UPDRS) Part III scores, wearing-off time, and discontinuation rate due to all causes. Secondary outcome measures were UPDRS total and subscale scores; discontinuation rates due to adverse events, inefficacy, and death; and individual adverse events. Results: Four randomized placebo-controlled trials including 1,068 PD patients were analyzed. All studies were conducted in Japan. UPDRS Part III scores were significantly lower with zonisamide than with placebo (weighted mean difference [WMD], -2.56; 95 confidence interval [CI]; -4.20 to -0.92; p=0.002). Further, zonisamide significantly decreased the wearing-off time compared with placebo (standardized mean difference, -0.24; 95 CI, -0.39 to -0.09; p=0.001). Discontinuation rates due to all causes were similar between the zonisamide and placebo groups (risk ratio, 1.29; 95 CI, 0.90 to 1.84; p=0.16). While zonisamide also decreased both UPDRS Part II (off-time) and UPDRS total scores compared to placebo (UPDRS Part II [off-time] scores: WMD, -0.79; UPDRS total scores: WMD, -2.51), there were no significant differences in other secondary outcomes between the two groups. Conclusions: Our results suggested that zonisamide combination therapy was beneficial in treating motor symptoms in PD patients receiving antiparkinson drugs and was well tolerated in Japanese patients. Future studies in populations other than the Japanese are needed.",
author = "Shinji Matsunaga and Taro Kishi and Nakao Iwata",
year = "2017",
month = "1",
day = "1",
doi = "10.3233/JAD-161068",
language = "English",
volume = "56",
pages = "1229--1239",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "4",

}

Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease : A Meta-Analysis. / Matsunaga, Shinji; Kishi, Taro; Iwata, Nakao.

In: Journal of Alzheimer's Disease, Vol. 56, No. 4, 01.01.2017, p. 1229-1239.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease

T2 - A Meta-Analysis

AU - Matsunaga, Shinji

AU - Kishi, Taro

AU - Iwata, Nakao

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: There is uncertainty about the efficacy and tolerability of zonisamide for Parkinson's disease (PD). Objective: We performed a meta-analysis of zonisamide treatment in PD patients who received antiparkinson drugs such as levodopa. Methods: The primary outcome measures were the Unified Parkinson's Disease Rating Scale (UPDRS) Part III scores, wearing-off time, and discontinuation rate due to all causes. Secondary outcome measures were UPDRS total and subscale scores; discontinuation rates due to adverse events, inefficacy, and death; and individual adverse events. Results: Four randomized placebo-controlled trials including 1,068 PD patients were analyzed. All studies were conducted in Japan. UPDRS Part III scores were significantly lower with zonisamide than with placebo (weighted mean difference [WMD], -2.56; 95 confidence interval [CI]; -4.20 to -0.92; p=0.002). Further, zonisamide significantly decreased the wearing-off time compared with placebo (standardized mean difference, -0.24; 95 CI, -0.39 to -0.09; p=0.001). Discontinuation rates due to all causes were similar between the zonisamide and placebo groups (risk ratio, 1.29; 95 CI, 0.90 to 1.84; p=0.16). While zonisamide also decreased both UPDRS Part II (off-time) and UPDRS total scores compared to placebo (UPDRS Part II [off-time] scores: WMD, -0.79; UPDRS total scores: WMD, -2.51), there were no significant differences in other secondary outcomes between the two groups. Conclusions: Our results suggested that zonisamide combination therapy was beneficial in treating motor symptoms in PD patients receiving antiparkinson drugs and was well tolerated in Japanese patients. Future studies in populations other than the Japanese are needed.

AB - Background: There is uncertainty about the efficacy and tolerability of zonisamide for Parkinson's disease (PD). Objective: We performed a meta-analysis of zonisamide treatment in PD patients who received antiparkinson drugs such as levodopa. Methods: The primary outcome measures were the Unified Parkinson's Disease Rating Scale (UPDRS) Part III scores, wearing-off time, and discontinuation rate due to all causes. Secondary outcome measures were UPDRS total and subscale scores; discontinuation rates due to adverse events, inefficacy, and death; and individual adverse events. Results: Four randomized placebo-controlled trials including 1,068 PD patients were analyzed. All studies were conducted in Japan. UPDRS Part III scores were significantly lower with zonisamide than with placebo (weighted mean difference [WMD], -2.56; 95 confidence interval [CI]; -4.20 to -0.92; p=0.002). Further, zonisamide significantly decreased the wearing-off time compared with placebo (standardized mean difference, -0.24; 95 CI, -0.39 to -0.09; p=0.001). Discontinuation rates due to all causes were similar between the zonisamide and placebo groups (risk ratio, 1.29; 95 CI, 0.90 to 1.84; p=0.16). While zonisamide also decreased both UPDRS Part II (off-time) and UPDRS total scores compared to placebo (UPDRS Part II [off-time] scores: WMD, -0.79; UPDRS total scores: WMD, -2.51), there were no significant differences in other secondary outcomes between the two groups. Conclusions: Our results suggested that zonisamide combination therapy was beneficial in treating motor symptoms in PD patients receiving antiparkinson drugs and was well tolerated in Japanese patients. Future studies in populations other than the Japanese are needed.

UR - http://www.scopus.com/inward/record.url?scp=85013484825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013484825&partnerID=8YFLogxK

U2 - 10.3233/JAD-161068

DO - 10.3233/JAD-161068

M3 - Article

C2 - 28157097

AN - SCOPUS:85013484825

VL - 56

SP - 1229

EP - 1239

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -